Suscribirse

Musculoskeletal corticosteroid injections: Recommendations of the French Society for Rheumatology (SFR) - 05/03/23

Doi : 10.1016/j.jbspin.2022.105515 
Yves Maugars a, , Hervé Bard b, Augustin Latourte c, Éric Senbel d, René-Marc Flipo e, Florent Eymard f

a French group multidisciplinary experts in interventional rheumatology

a Service de rhumatologie, CHU Nantes, Nantes, France 
b Rhumatologie, Paris, France 
c Service de rhumatologie, CHU Lariboisière, Paris, France 
d Rhumatologie, Marseille, France 
e Service de rhumatologie, CHU Lille, Lille, France 
f Service de rhumatologie, CHU Henri-Mondor, Paris, France 

Corresponding author. Service de rhumatologie, CHU Nantes, 1, place Alexis-Ricordeau, 44093 Nantes, France.Service de rhumatologie, CHU Nantes1, place Alexis-RicordeauNantes44093France

Highlights

Corticosteroid injections are a standard practice seeing increasing use.
The choice of which corticosteroids to use and their availability is an on-going discussion.
Technical advances and very rare complications justify updating our practices.
A group of multidisciplinary experts has drawn up 13 consensus-based recommendations.
The role of corticosteroid injections must be defined relative to new joint regenerative therapies.

El texto completo de este artículo está disponible en PDF.

Abstract

Musculoskeletal corticosteroid injections are widely performed, although the exact practice varies greatly due to advances in knowledge and techniques. This justifies updating and drawing up good practice recommendations. Using a consensus model formalized by the French National Authority for Health (HAS) and based on a literature review that resulted in a “white book”, 13 recommendations were developed by a group of experts. These recommendations were then sent online to 48 specialists for evaluation, 27 of whom were rheumatologists and 15 of whom were general practitioners. These recommendations were also presented at the 34th annual meeting of the French Society for Rheumatology (SFR) (Paris, December 2021) at a symposium attended by a hundred or so rheumatologists, who voted on these recommendations in person. The results are presented as an overall score out of 10, a median out of 10 and as tertiles. The agreement was excellent for 10 of these 13 recommendations, with mean values of 8.5 to 9.1 out of 10, median values of 9 or 10 out of 10 and agreement of 91.7% to 97.9%, which corresponds to a consensus. The 3 other recommendations were broadly supported but were the subject of more debate. One relates to patient information (mean 7.3/10, median 8/10, upper tertile 72.9%) with discussion about the waiting period. Another related to the summary report (mean 8.4/10, median 9, upper tertile 91.7%) with discussions about its content and the need to specify the lot number of the injected product. The last one related to periprosthetic injections and the need to consult and get approval from a specialist (mean 8.0/10, median 8, upper tertile 83.3%) with mostly the general practitioners having reservations. In all, there is a very strong consensus among the musculoskeletal corticosteroid injection experts and specialists consulted, which justifies them being taken into consideration to improve our daily practice.

El texto completo de este artículo está disponible en PDF.

Keywords : Cortisone injection, Injection, Corticosteroids, Recommendations


Esquema


© 2022  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 90 - N° 2

Artículo 105515- mars 2023 Regresar al número
Artículo precedente Artículo precedente
  • Inhibiting C5a/C5aR to treat ANCA-associated vasculitides
  • Benjamin Terrier, Alexandre Karras
| Artículo siguiente Artículo siguiente
  • Autoimmune epithelitis in primary Sjögren's syndrome
  • Emiko Desvaux, Jacques-Olivier Pers

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.